





Immunization Branch

Immunization Updates for Providers


Friday, November 15, 2024
9:00 am – 10:30 am



Q&A



During today's webinar, please click and open the Q&A icon to ask your questions so CDPH panelists and subject matter experts (SMEs) can respond.



[Links are in blue and underlined](#)

Housekeeping

Reminder to Attendees:



Today's session is being recorded. For slides, webinar recordings, and other postings, see the

[CDPH Weekly Immunization Updates for Providers](#).



To be added to the CDPH email messaging listserv for providers, please email your request to blanca.corona@cdph.ca.gov.



If you have post-webinar-related questions, please email leslie.amani@cdph.ca.gov.

Agenda: Friday, November 15, 2024

No.	Topic	Presenters (CDPH)	Time (AM)
1	Welcome and Announcements	Leslie Amani	9:00 – 9:05
2	COVID-19 Vaccine Administration Data	Sarah Stich	9:05 – 9:10
3	CA Immunization Registry	Michael Powell	9:10 – 9:15
4	CA Bridge Access Program	Claudia Aguiluz	9:15 – 9:20
5	Vaccines for Children (VFC) Program	Brenton Louie	9:20 – 9:25
6	Clinical	Floria Chi, MD	9:25 – 9:35
7	Vaccine Management (My Turn / myCAvax)	Josh Pocus and Claudia Aguiluz	9:35 – 9:45
8	Resources and Q&A	Leslie Amani and CDPH SMEs	9:45 – 10:30

Announcements

Leslie Amani, CDPH



**OLDER ADULTS NEED
VACCINE PROTECTION FROM
FLU, RSV & COVID-19.**





VFC Afternoon TEAch Webinar



Date: Thursday, December 5, 2024

Time: 12:00 – 1:00PM, PT

Topic: What's New with Winter Respiratory Viruses

Register: [VFC Afternoon TEAch Webinar Zoom Registration Link](#)



VFA Webinar

Looking Ahead: 2025 Recertification Essentials, Program Updates and ACIP Updates



Date: Wednesday, December 11, 2024
Time: 12:00 – 1:00PM, PT

Topics: 2025 Recertification Process, Program and Eligibility Updates, ACIP Updates

Intended Audience: VFA Key Practice Staff

[VFA Webinar Registration Link](#)

Calendario de la Vacuna COVID-19 2024 – 2025

Calendario de la vacuna COVID-19 2024-25 –Calendario Rutinario			
Para obtener la versión en línea y los detalles, consulte las Consideraciones clínicas provisionales para el uso de vacunas contra el COVID-19 . El calendario está sujeto a cambios			
Edad*	Vacuna	Si no está vacunado:	Si ha tenido alguna dosis previa, dé 2024-25 dosis:
6 meses–4 años†	Pfizer–Bebés y niños pequeños	1ra Dosis → 3-8 semanas → 2da Dosis → ≥8 semanas → 3ra Dosis	Si 1 dosis previa, entonces: 3-8 semanas 1 ≥8 semanas 2 Si ≥2 dosis previas, entonces: ≥8 semanas 1
	Moderna–Pediatría	1ra Dosis → 4-8 semanas → 2da Dosis	Si 1 dosis previa, entonces: 4-8 semanas 1 Si ≥2 dosis previas, entonces: ≥8 semanas 1
5–11 años	Moderna–Pediatría	1 Dosis	Si 1 o más dosis anteriores (de cualquiera de las marcas), entonces ^Δ : ≥2 meses [§] 1 2024-25 Moderna/Pfizer/Novavax
	Pfizer–Pediatría	1 Dosis	
12+ años	Pfizer–Adol/Adulto (Comirnaty)	1 Dosis	Si 1 o más dosis anteriores (de cualquiera de las marcas), entonces ^Δ : 12-64 años: ≥2 meses 1 2024-25 Moderna/Pfizer/Novavax 65+ años: ≥2 months 1 6 months [§] 2
	Moderna–Adol/Adulto (Spikevax)	1 Dosis	
	Novavax	1ra Dosis → 3-8 semanas → 2da Dosis	

* Consulte las [recomendaciones de los CDC](#) para los niños que hacen la transición de una edad menor a una edad mayor
† Los niños de 6 meses a 4 años deben recibir la misma marca de la vacuna actualizada que las dosis anteriores que recibieron.
** Un [intervalo de 8 semanas](#) puede ser preferible para algunas personas, especialmente para los varones de 12 a 39 años.
‡ Todas las dosis de Moderna de 6 meses a 11 años son de 0.25 ml (25 mcg).
Δ La vacuna Janssen (J & J) ha sido desautorizada. Siga el calendario para mayores de 12 años para cualquier dosis anterior
§ Intervalo mínimo de 2 meses.
¶ Si han transcurrido más de 8 semanas desde la primera dosis de Novavax, puede administrarse cualquier vacuna COVID-19 2024-25 (Moderna/Pfizer/Novavax).

Calendario de la Vacuna COVID-19 2024-25 si está moderada o gravemente inmunocomprometido			
Edad	Vacuna	Si no está vacunado:	Si recibió alguna dosis anterior administre 2024-25 dosis:
6 meses–4 años	Pfizer–Bebés y niños pequeños	1ra Dosis → 3 semanas → 2da Dosis → ≥8 semanas → 3ra Dosis → 6 meses [§] → Dosis Adicional*	1 dosis previa: 3 s 1 ≥8 s 2 ≥2 dosis previas: ≥8 s 1
	Moderna–Pediatría	1ra Dosis → 4 semanas → 2da Dosis → ≥4 semanas → 3ra Dosis → 6 meses [§] → Dosis Adicional*	1 dosis previa: 4 s 1 ≥4 s 2 2 dosis previas: ≥4 s 1
5–11 años	Moderna–Pediatría	1ra Dosis → 4 semanas → 2da Dosis → ≥4 semanas → 3ra Dosis → 6 meses [§] → Dosis Adicional*	≥3 dosis previas** ≥8 s 1
	Pfizer–Pediatría	1ra Dosis → 3 semanas → 2da Dosis → ≥4 semanas → 3ra Dosis → 6 meses [§] → Dosis Adicional*	1 dosis previa: 3 s 1 ≥4 s 2 2 dosis previas: ≥4 s 1
12+ años	Pfizer–Adol/Adulto (Comirnaty)	1ra Dosis → 3 semanas → 2da Dosis → ≥4 semanas → 3ra Dosis → 6 meses [§] → Dosis Adicional*	≥3 dosis previas** ≥8 s 1
	Moderna–Adol/Adulto (Spikevax)	1ra Dosis → 4 semanas → 2da Dosis → ≥4 semanas → 3ra Dosis → 6 meses [§] → Dosis Adicional*	1 dosis previa: 4 s 1 ≥4 s 2 2 dosis previas: ≥4 s 1
	Novavax	1ra Dosis → 3 semanas → 2da Dosis → 6 meses [§] → Dosis Adicional*	≥3 dosis previas** ≥8 s 1

* Pueden administrarse **dosis adicionales** bajo decisión clínica compartida con un intervalo mínimo de 2 meses. Vea la [Tabla 2](#) para el vial y la dosis
** A los niños de 5 a 11 años se puede administrar Moderna o Pfizer después de ≥3 dosis previas. Los mayores de 12 años pueden recibir Moderna, Pfizer o Novavax.
§ Intervalo mínimo de 2 meses.
¶ Si han transcurrido más de 8 semanas desde la primera dosis de Novavax, puede administrarse cualquier vacuna COVID-19 2024-25 (Moderna/Pfizer/Novavax).

Calendario de la Vacuna COVID-19 2024 - 2025

Webinar Calendar: November 2024

November is Native American Heritage Month

Sunday	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
November is National Long-term Care Awareness Month					1 Provider Webinar	2
3 Daylight Saving Time	4	5	6	7	8	9
10 World Immunization Day	11 Veteran's Day	12	13	14	15 Provider Webinar	16
17	18	19	20	21  National Rural Public Health Day	22	23
24	25 Thank you! 	26	27	28  Thanksgiving Day	29 No Provider Webinar	30

Webinar Calendar: December 2024

Sunday	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
1	2	3	4	5	6	7
8	9	10	11	12	13 Provider Webinar	14
15	16	17	18	19	20	21
22	23	24 Christmas Eve	25 Christmas Day Hanukkah – Jan 2	26 Kwanzaa – Jan 1	27	28
29	30	31 New Year's Eve	January 1, 2025 New Year's Day			

COVID-19 Vaccine Administration Data

Sarah Stich, CDPH


COVID-19 Vaccine Administration Summary

as of November 8, 2024

100,589,505


Total Doses Administered:

Daily Doses Administered: **Statewide**



3,764,094

2024-2025 COVID-19 Recipients



Trends in COVID-19 Vaccine Administration


as of November 8, 2024

CDC recommends the 2024-25 COVID-19 vaccine for everyone 6 months and older


An updated vaccine protects against:

- ✓ COVID-19 variants spreading now
- ✓ Severe illness, hospitalization, and death






bit.ly/mm7337e2
SEPTEMBER 10, 2024



[CDC- 2024-2025 COVID-19 Vaccine Recommendation](#)

[CDC- Staying Up to Date](#)

Doses Administered by Age Group, Past 4 Weeks




COVID-19 Vaccine Uptake Comparison

as of November 8, 2024

Current vs Last Year's COVID-19 Vaccine Dose Uptake by % of Population in 77 days since EUA

■ Updated 2024-2025 Doses ■ Updated 2023-2024 Doses



Current COVID-19 vaccine uptake is similar to what we saw last year, a 0.3% difference

COVID-19 Vaccine Uptake Comparison by Age

as of November 8, 2024


Age Group: % of Population by Vaccine Status:

Up To Date | Received 2023-2024 Dose but Not Up to Date | Any Shot but Not Up To Date | No Shots

- Highest uptake in the 65+ population
- About 50% of those who received a 2023-2024 dose last year have yet to receive this season's dose

During October 2023–April 2024, adults aged ≥65 years accounted for 70% of all COVID-19–associated hospitalizations among adults. Most hospitalized adults had multiple underlying medical conditions. Only 12% had received the recommended COVID-19 2023–2024 formula vaccine.

[CDC – COVID-19 Associated Hospitalizations MMWR](#)




COVID-19 Vaccination Overview

as of November 8, 2024


% of Population Up-to-Date: Statewide 9.6%

Above State Average | Below State Average


By County




By HPI Quartile



By Race/Ethnicity



By Age Group



[Public Dashboard Link](#)

System Notes

- Up-to-Date status defined as at least one dose of the updated 2024 – 2025 COVID-19 vaccine
- Email cdphvaccinatedatateam@cdph.ca.gov for questions and comments.

[Public Dashboard Link](#)

California Immunization Registry

Michael Powell, CDPH

CAIR2 Release Roadmap

Past Release

November 3, 2024 (2.8.19)

Sprint 17

User Interface

- ✓ PPSV23 bug in children under 5 yo
- ✓ New COVID vaccines (2024-2025 Formula)
- ✓ Add Trivalent Flu vaccines to Influenza series
- ✓ Update Last WS Submission Field
- ✓ Remove CPT code 90726 from CVX 90
- ✓ Remove Flucelvax NDC from ONB & TRN

Data Exchange

- ✓ New COVID vaccines (2024-2025 Formula)
- ✓ Add Trivalent Flu vaccines to Influenza series
- ✓ Update Last WS Submission Field
- ✓ Remove CPT code 90726 from CVX 90
- ✓ Upgrade the MyBatis jar file used by CAIR DX and Runmatch to current version
- ✓ A dose amount of '1.0' is returned in RXA-6 for all VXP messages
- ✓ ACK fixes
- ✓ Allow "Md" to the name fields
- ✓ Remove Flucelvax NDC from ONB & TRN

Technical

- ✓ Upgrade the MyBatis jar file used by CAIR DX and Runmatch to current version
- ✓ Capture IP Address upon login

Current

November 20, 2024 (2.8.20)

Sprint 18

User Interface

- ✓ Add New vaccine Vaxchora
- ✓ Remove "Parent Recall" from Source of Imm list
- ✓ Add Polio Oral to historical Add details dropdown
- ✓ 2024-2025 COVID Seasonal Schedule
- ✓ Update NOS vaccines to carry "unspecified" trade names

Data Exchange

- ✓ Add New vaccine Vaxchora
- ✓ Remove "Parent Recall" from Source of Imm list
- ✓ Add Polio Oral to historical Add details dropdown
- ✓ 2024-2025 COVID Seasonal Schedule
- ✓ Update NOS vaccines to carry "unspecified" trade names
- ✓ Collect SOGISC Data (Research)
- ✓ Sub race code issue on pending clients

Technical

- ✓ Sub race code issue on pending clients

Future Release

TBD

Upcoming Releases

User Interface

- ✓ Add CVX & NDC to Edit Immunization Screen
- ✓ PCV Child Schedule
- ✓ PCV 21 Schedule Updates
- ✓ Adding New Immunizations using the Activate Expired button
- ✓ Update RSV Adult Schedule Recommendation
- ✓ Menactra NDCs Cleanup
- ✓ New Avian Influenza CVX codes

Data Exchange

- ✓ Add CVX & NDC to Edit Immunization Screen
- ✓ OBX Segments Updated - Inbound
- ✓ VIS OBX Segments
- ✓ Update RSP RXA-6 and RXA-7
- ✓ PCV 21 Schedule Updates
- ✓ Update RSV Adult Schedule Recommendation
- ✓ Menactra NDCs Cleanup
- ✓ New Avian Influenza CVX codes

Technical

- ✓ Increase the DB Column Size for all Org IDs in the CAIR DB
- ✓ Address ID Cleanup Research
- ✓ Bug within the Restore Patient Search Screen
- ✓ Menactra NDCs Cleanup

DVR Release Roadmap

Past Release

October 29, 2024 (UR76)

Unified Release 76

DVR Front End

- ✓ Enhance DVR Navigation Bar to provide better user experience for residents
- ✓ Eliminate recipient's name from AWS Lambda requests and logs to limit non-essential user data transmission

DVR Integration

- ✓ Removal of outdated Iceberg data from prior consolidation efforts that are no longer needed
- ✓ Update Stage environment to truncate tables in Databricks

Staff Remediation Tool (SRT)

- ✓ Cleanup of obsolete backend components following Auto-Remediation optimization

Virtual Assistant Tool (VAT)

- ✓ Continue regular security upgrades, reporting, and monitoring

Current

December 10, 2024 (UR77)

Unified Release 77

DVR Front End

- ✓ Update "Need Help" section on the DVR Landing page to include stronger verbiage for residents calling the CAIR Help Desk
- ✓ Update DVR site, Email Templates, and PDFs with latest CDPH/My DVR logo and branding
- ✓ Upgrade to newest Evaluator version to support new RSV Vaccine Group
- ✓ Release Google Wallet integration for Android users to save CA Immunization Record to mobile devices
- ✓ Enhance FAQ page search feature to provide direct and most-similar matches

DVR Integration

- ✓ Enable logging and monitoring of key metrics and alert configurations
- ✓ Removal of outdated ADF global parameters that are no longer needed

Staff Remediation Tool (SRT)

- ✓ Update SRT Email Templates with latest CDPH/My DVR logo and branding
- ✓ Optimize Azure SQL Database compute resources
- ✓ Enhance security by transitioning to Managed Identity

Virtual Assistant Tool (VAT)

- ✓ Continue regular security upgrades, reporting, and monitoring

Future

(UR78+ until EOY)

Upcoming Unified Releases

DVR Front End

- ✓ Phase 2 FAQ page search feature enhancement to enable fuzzy matching across all pages
- ✓ Evaluator Series and Booster dose logic enhancements to the CA Immunization Record
- ✓ Enhance DOB field for usability

DVR Integration

- ✓ Optimize backend Databricks API calls and enhance alerts for merged records
- ✓ Repoint views in DVR pipelines

Staff Remediation Tool (SRT)

- ✓ Enhance User Management page to add/inactive users
- ✓ Ticket History enhancement to display all changes made to a ticket
- ✓ Consolidate CVX codes to backend mapping table that will capture any new CVX code

Virtual Assistant Tool (VAT)

- ✓ Continue regular security upgrades, reporting, and monitoring

Contact Information



- CAIR Contact Information
 - General Information
 - [California Immunization Registry](#)
 - Help Desk
 - CAIRHelpDesk@cdph.ca.gov
 - 800-578-7889
 - Data Exchange
 - CAIRDataExchange@cdph.ca.gov
 - My DVR
 - [Digital Vaccine Record \(ca.gov\)](#)
 - [DVR Virtual Assistant](#)

CA Bridge Access Program

Claudia Aguiluz, CDPH

CA BAP Funding and Ordering 2024 – 2025

Funding: Section 317 COVID-19 funding supports ordering for vaccines provided through the California Bridge Access Program.

FFY	317 Funds	Overall Vaccine Ordering Limits	Ordered Doses	% Budget Consumed
2024 – 2025	5.9M	69K	*23,180	*34%

*As of 11/12/24

CA BAP Seasonal Allocations

- Full COVID-19 CA BAP vaccine allocations have been distributed to LHDs with a very small amount kept in CDPH reserve for additional urgent needs.
- Once depleted, any pending orders for COVID-19 brands that LHDs no longer have inventory to approve will need to be rejected.
- Providers may then request a new order of the available product or the LHD may submit the order on behalf of the provider.
- **Providers must be made aware if a new product is being requested for them due to storage unit preparation.**









COVID-19 Vaccine Product Guide

COVID-19 Vaccine Product Guide

CDPH

Check vaccine labels and FDA materials before use to avoid mix-ups.

Package inserts and EUA fact sheets supersede info on vials and carton.

Pfizer				
	Infant/Toddler 6 months–4 years	Pediatric 5–11 years	Comirnaty 12+ years	Comirnaty 12+ years
			Single-Dose Vial 2024-25 Formula image not available	
	2024-25 Formula	2024-25 Formula		2024-25 Formula
Packaging	Yellow Cap	Blue Cap		Pre-Filled Syringe
Doses Per Vial	3 doses	1 dose	1 dose	1 dose/syringe
Carton Size	30 doses	10 doses	10 doses	10 doses
NDC-Unit of Sale (carton)	59267-4426-02	59267-4438-02	00069-2403-10	00069-2432-10
NDC-Unit of Use (vial/syringe)	59267-4426-01	59267-4438-01	00069-2403-01	00069-2432-01
CVX Code	308	310	309	309
CPT Code	91318	91319	91320	91320
Program Availability	VFC	VFC	Not available	VFC, CA BAP
Min. Standard Order*	30 doses	10 doses	N/A	10 doses
Storage Limits Before Puncture: Label vaccine with expiration and use-by dates.				
Shipping	Ships from manufacturer with dry ice between -90°C and -60°C (-130°F to -76°F)			2° to 8°C (36°F to 46°F)
ULT	Until expiration date at -90°C to -60°C (-130°F to -76°F)			
Thermal Shipper				
Freezer				
Refrigerator	Up to 10 weeks at 2°C to 8°C (36°F to 46°F). Do not refreeze. Write the use-by date on carton—not to exceed expiration.			Until expiration at 2°C to 8°C
Expiration Date	Check the date on the product/carton, or for thawed products refer to the written use-by date.			Check label.
Administration				
Diluent (supplied)	1.1 mL per vial	Do not dilute	Do not dilute	N/A
Dose Volume & Dose	0.3 mL 3 mcg dose	0.3 mL 10 mcg dose	0.3 mL 30 mcg dose	0.3 mL 30 mcg dose
Refrigerator Thaw Time	Carton/Vial: Up to 2 hours at 2° to 8°C (36°F to 46°F) (Do not refreeze)			N/A
Room Temp Thaw Time	Vial: 30 minutes at up to 25°C (77°F) (Do not refreeze)			N/A
Total Time at				













Vaccines for Children (VFC)

Brenton Louie, CDPH

Basics of Vaccine Ordering

- Vaccine Order Form
- Transfers Sent/Received and Waste
- Provider Inventories

Vaccine Order Form

Vaccine Products		VFC On-hand Inventory		VFC Doses administered		Provider inventory		Order size	
Vaccine product	*Quantity	Lot number ⓘ	Expiration Date / Beyond use date ⓘ	*Qty since last order ⓘ	Estimated Provider inventory ⓘ	Variance ⓘ	Recommended Order size ⓘ	*Doses requested	
DTaP	Daptacel Single Dose Vials - 10 Per Box	<input type="text"/>	<input type="text"/>  +	<input type="text"/>	<input type="text"/>		<input type="text"/>	<input type="text" value="0"/>  Clear Row	
	Infanrix Single Dose Syringes - 10 Per Box	<input type="text"/>	<input type="text"/>  +	<input type="text"/>	<input type="text"/>		<input type="text"/>	<input type="text" value="0"/>  Clear Row	
DTaP/IPV	Kinrix Single Dose Syringes - 10 Per Box	<input type="text"/>	<input type="text"/>  +	<input type="text"/>	<input type="text"/>		<input type="text"/>	<input type="text" value="0"/>  Clear Row	
	Quadracel Single Dose Syringes - 10 Per Box	<input type="text"/>	<input type="text"/>  +	<input type="text"/>	<input type="text"/>		<input type="text"/>	<input type="text" value="0"/>  Clear Row	
	Quadracel Single Dose Vials (2025 expiry)- 10 Per Box	<input type="text"/>	<input type="text"/>  +	<input type="text"/>	<input type="text"/>		<input type="text"/>	<input type="text" value="0"/>  Clear Row	

On-hand Inventory

Vaccine Products

VFC On-hand Inventory

VFC Doses administered

Provider inventory

Order size

Vaccine product	*Quantity	Lot number ⓘ	Expiration Date / Beyond use date ⓘ	*Qty since last order ⓘ	Estimated Provider inventory ⓘ	Variance ⓘ	Recommended Order size ⓘ	*Doses requested
DTaP	Daptacel Single Dose Vials - 10 Per Box	<input type="text"/>	<input type="text"/> ⓘ +	<input type="text"/>	<input type="text"/>		<input type="text"/>	0 <input type="text"/> ⓘ Clear Row
	Infanrix Single Dose Syringes - 10 Per Box	<input type="text"/>	<input type="text"/> ⓘ +	<input type="text"/>	<input type="text"/>		<input type="text"/>	0 <input type="text"/> ⓘ Clear Row
DTaP/IPV	Kinrix Single Dose Syringes - 10 Per Box	<input type="text"/>	<input type="text"/> ⓘ +	<input type="text"/>	<input type="text"/>		<input type="text"/>	0 <input type="text"/> ⓘ Clear Row
	Quadracel Single Dose Syringes - 10 Per Box	<input type="text"/>	<input type="text"/> ⓘ +	<input type="text"/>	<input type="text"/>		<input type="text"/>	0 <input type="text"/> ⓘ Clear Row
	Quadracel Single Dose Vials (2025 expiry)- 10 Per Box	<input type="text"/>	<input type="text"/> ⓘ +	<input type="text"/>	<input type="text"/>		<input type="text"/>	0 <input type="text"/> ⓘ Clear Row

Doses Administered

Vaccine Products		VFC On-hand Inventory			VFC Doses administered	Provider inventory		Order size	
Vaccine product	*Quantity	Lot number ⓘ	Expiration Date / Beyond use date ⓘ	*Qty since last order ⓘ	Estimated Provider inventory ⓘ	Variance ⓘ	Recommended Order size ⓘ	*Doses requested	
DTaP	Daptacel Single Dose Vials - 10 Per Box	<input type="text"/>	<input type="text"/>	<input type="text"/> ⓘ +	<input type="text"/>	<input type="text"/>	<input type="text"/>	0 <input type="text"/> ⓘ Clear Row	
	Infanrix Single Dose Syringes - 10 Per Box	<input type="text"/>	<input type="text"/>	<input type="text"/> ⓘ +	<input type="text"/>	<input type="text"/>	<input type="text"/>	0 <input type="text"/> ⓘ Clear Row	
DTaP/IPV	Kinrix Single Dose Syringes - 10 Per Box	<input type="text"/>	<input type="text"/>	<input type="text"/> ⓘ +	<input type="text"/>	<input type="text"/>	<input type="text"/>	0 <input type="text"/> ⓘ Clear Row	
	Quadracel Single Dose Syringes - 10 Per Box	<input type="text"/>	<input type="text"/>	<input type="text"/> ⓘ +	<input type="text"/>	<input type="text"/>	<input type="text"/>	0 <input type="text"/> ⓘ Clear Row	
	Quadracel Single Dose Vials (2025 expiry)- 10 Per Box	<input type="text"/>	<input type="text"/>	<input type="text"/> ⓘ +	<input type="text"/>	<input type="text"/>	<input type="text"/>	0 <input type="text"/> ⓘ Clear Row	

Doses Requested

Vaccine Products		VFC On-hand Inventory		VFC Doses administered		Provider inventory		Order size		
Vaccine product	*Quantity	Lot number ⓘ	Expiration Date / Beyond use date ⓘ	*Qty since last order ⓘ	Estimated Provider inventory ⓘ	Variance ⓘ	Recommended Order size ⓘ	*Doses requested		
DTaP	Daptacel Single Dose Vials - 10 Per Box	<input type="text"/>	<input type="text"/>	<input type="text"/> +	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/> 0	Clear Row	
	Infanrix Single Dose Syringes - 10 Per Box	<input type="text"/>	<input type="text"/>	<input type="text"/> +	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/> 0	Clear Row	
DTaP/IPV	Kinrix Single Dose Syringes - 10 Per Box	<input type="text"/>	<input type="text"/>	<input type="text"/> +	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/> 0	Clear Row	
	Quadracel Single Dose Syringes - 10 Per Box	<input type="text"/>	<input type="text"/>	<input type="text"/> +	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/> 0	Clear Row	
	Quadracel Single Dose Vials (2025 expiry)- 10 Per Box	<input type="text"/>	<input type="text"/>	<input type="text"/> +	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/> 0	Clear Row	

Transfers and Waste

Adds doses to your account

- Transfers Received

Removes doses from your account

- Transfers Sent
- Waste




All events above must be reported on the Transfer or Waste form, and **not** on the vaccine order form.

Provider Inventories

- Running balances of inventory for each vaccine brand/presentation ordered.
- Decrementing by doses administered data from vaccine orders, transfers sent, and waste.
- Incrementing by doses requested and received from vaccine orders.


Provider Inventories – Order Request Page



HomeMy ProgramsMy Turn ▾Vaccine OrdersProgram LocationsVaccine Inventory ▾More ▾

🔍🔔👤

🔗 Need help? Review the job aid(s) for [placing vaccine order requests](#), [understanding provider inventory](#), [VFC product guide](#), [shipping cadence](#) and [managing storage units](#).




VFC - Order Request

Step 1 - Select Account and Product

To change the program selected, navigate back to the [Vaccine Orders page](#).

* Program Location



Vaccines for Children

✕

Select Location, Provide Inventory and Doses Administered for Vaccines listed.

- Ensure the current VFC inventory in your vaccine storage units matches the On-hand Inventory you enter.
- Your VFC Doses Administered inventory must match the immunization registry (CAIR/Healthy Futures).
- View the provider inventory link below to account for every dose your location has received. If your calculated provider inventory does not match, please ensure that you have reported all transfers, waste events, and returns prior to this order request.

Next Order Due Date (approximate) ⓘ	Provider Inventory ⓘ	Practice Volume & Order Frequency ⓘ
December 22, 2024	View Provider Inventory	Low (every 3 months)

Provider Inventories – Program Locations Page

The screenshot shows the myCAVax interface. The top navigation bar includes links for Home, My Programs, My Turn, Vaccine Orders, Program Locations (circled in red), Vaccine Inventory, and More. A red arrow points from the circled 'Program Locations' link to the 'Vaccine Inventories' tab in the sub-header. The sub-header also shows a 'Program Location' card for 'Vaccines for Children' with buttons for '+ Follow', 'Update Address', and 'Edit'. Below the sub-header, the 'Vaccine Inventories' tab is selected and circled in red. The main content area displays a table of provider inventories.

Program Location - Vaccines for Children

+ Follow Update Address Edit


PIN LHD/MCE myCAVax.Id Temporary Closure IIS Identifier

Details Vaccine Requests Storage and Handling **Vaccine Inventories** Site


Provider Inventories (82)

Provider Inventory Name	Product	Available Quantity	Total to be Allocated by CDPH	Allocation Received to Date	Doses Available to Order
PI-628954	TDVAX Vaccine Single Dose Vials - ...	34	0	-20	
PI-627871	Boostrix Single Dose Syringes - 10 ...	31	0	-30	
PI-627502	Pfizer 2023-2024 (6mos - 4yrs) Mul...	0	0	0	
PI-624113	ActHIB Single Dose Vials - 5 Per Box	10	0	-10	
PI-623568	Engerix B Single Dose Syringes - 1...	26	0	-40	
PI-619577	Pfizer 2023-2024 (5yrs - 11yrs) Sin...	0	0	0	

Provider Inventories – Vaccine Details



HomeMy ProgramsMy TurnVaccine OrdersProgram Locations

 Provider Inventory
PI-628954

DETAILS

RELATED

Provider Inventory Name

PI-628954

Account

Program Location

Product

[TDVAX Vaccine Single Dose Vials - 10 Per Box](#)

Available Quantity

34

Allocation Details


Total to be Allocated by CDPH

Allocation Received to Date


0

Doses Available to Order

-20



HomeMy ProgramsMy TurnVaccine OrdersProgram Locations

 Provider Inventory
PI-628954


DETAILS

RELATED

Inventory Summary (6+)


Inventory Summary Name	Transaction Type	Total Quantity	Created Date	
IS-912150	Manual Adjustment	1	4/25/2024, 12:00 AM	
IS-912151	Manual Adjustment	10	4/25/2024, 12:00 AM	
IS-912152	Manual Adjustment	10	4/25/2024, 12:00 AM	
IS-983389	Dose Administration	-2	6/21/2024, 2:10 PM	
IS-1048464	Shipment	20	8/6/2024, 10:00 AM	
IS-1093506	Dose Administration	-2	8/15/2024, 7:42 PM	

View All

 Provider Inventory History (2)

Date	Field	User	Original Value	New Value	
6/7/2024, 11:38 AM	Created.	User1614278695298...			
6/7/2024, 11:38 AM	Provider Inventory Name	User1614278695298...		PI-628954	

View All



Immunization
Branch

35

Nirsevimab Supply Availability






- Nirsevimab (Beyfortus™) continues to be available to order from VFC to prevent severe respiratory syncytial virus (RSV) disease in VFC-eligible infants and toddlers.
- RSV is the leading cause of infant hospitalization in the U.S, with an estimated 58,000-80,000 children younger than 5 years hospitalized each year due to RSV infection, with infants being among those at greatest risk.
- Throughout the RSV season, please ensure your clinic has doses of nirsevimab available for administration to infants.
- If you are unable to submit an order due to an existing order for your account that is currently being fulfilled (i.e. status of Submitted, Assigned, Corrections Needed, Corrections Submitted, Pending, Approved), please contact our VFC Customer Service Center at 877-243-8832 for assistance.

Clinical

Floria Chi, MD, MPH, CDPH

CDPH Weekly Respiratory Virus Report

Data from October 27-November 2, 2024

	COVID-19	FLU	RSV
 Test Positivity (change)	3.5% (0.6)	2.1% (0.4)	2.0% (0.3)
 Percent of Total Admissions (change)	N/A	N/A	0.2% (0.1)
 Percent of Total Deaths (change)	0.8% (0.0)	0.0% (0.0)	0.1% (0.1)
 Total Season Pediatric Deaths (new)	3 (1)	1 (0)	0 (0)
 Wastewater Concentrations (trend)	LOW (DECREASING)	N/A	N/A

Key Messages

- RSV activity is starting to increase. COVID-19 and influenza activity are currently low in California.
- The most prevalent COVID-19 variant lineages continue to be descendants of JN.1

- Contains COVID-19, influenza and RSV surveillance metrics
- Replaces the CDPH Respiratory Dashboard and the weekly Flu and Respiratory Virus Surveillance Report
- Report link: [CDPH Respiratory Virus Report](#)

Updated COVID-19 Vaccine Information Sheet (VIS)

VACCINE INFORMATION STATEMENT

COVID-19 Vaccine:

What You Need to Know

Many vaccine information statements are available in Spanish and other languages. See www.immunize.org/vi

Hojas de información sobre vacunas están disponibles en español y en muchos otros idiomas. Visite www.immunize.org/vi

1. Why get vaccinated?

COVID-19 vaccine can prevent COVID-19 disease. Vaccination can help reduce the severity of COVID-19 disease if you get sick.

COVID-19 is caused by a coronavirus called SARS-CoV-2 that spreads easily from person to person. COVID-19 can be mild to moderate, lasting only a few days, or it can be severe, requiring hospitalization, intensive care, or a ventilator to help with breathing. COVID-19 can also result in death.

COVID-19 symptoms may appear 2 to 14 days after exposure to the virus. A person can have mild, moderate, or severe symptoms.

- Symptoms can include fever; chills; cough; shortness of breath or difficulty breathing; fatigue (tiredness); muscle or body aches; headache; new loss of taste or smell; sore throat; congestion or runny nose; nausea; vomiting; and diarrhea.
- More serious symptoms can include trouble breathing; persistent pain or pressure in the chest; new confusion; inability to wake or stay awake; and pale, gray, or blue-colored skin, lips, or nail beds (depending on skin tone).

Older adults and people of any age with certain underlying medical conditions (like heart or lung disease or diabetes) are more likely to get very sick with COVID-19.

After COVID-19 illness, some people get Long COVID, a chronic condition with symptoms lasting 3 months or longer. Symptoms of Long COVID may get better, get worse, or stay the same.

People who are up to date with COVID-19 vaccination have a lower risk of severe illness, hospitalization, and death from COVID-19 than people who are not up to date. COVID-19 vaccination is the best way to prevent Long COVID.

Getting a COVID-19 vaccine helps the body learn how to defend itself from the disease and reduces the risk for severe illness and complications. Additionally, COVID-19 vaccines can offer added protection to people who have already had COVID-19, including protection against being hospitalized if they become infected with COVID-19 again.

2. COVID-19 vaccine

Updated 2024–2025 COVID-19 vaccine is recommended for everyone 6 months of age and older. This includes people who are pregnant, breastfeeding, trying to get pregnant now, or who might become pregnant in the future.

2024–2025 COVID-19 vaccines for infants and children 6 months through 11 years of age are available under Emergency Use Authorization from the U. S. Food and Drug Administration (FDA). Please refer to the Fact Sheets for Recipients and Caregivers for more information.

For people 12 years of age and older, 2024–2025 COVID-19 vaccines, manufactured by ModernaTX, Inc. or Pfizer, Inc., are approved by FDA.

Novavax COVID-19 Vaccine Adjuvanted (2024–2025 Formula) vaccine is available under Emergency Use Authorization from FDA for people 12 years and older. Please refer to the Fact Sheet for Recipients and Caregivers for more information.

- **Everyone 6 months of age and older** is recommended to receive an age-appropriate FDA-approved or authorized updated 2024–2025 COVID-19 vaccine.
- **Certain people, such as those who have medical conditions or are taking medications that affect the immune system**, may need additional doses of COVID-19 vaccine. Your health care provider can advise you.



U.S. CENTERS FOR DISEASE CONTROL AND PREVENTION

3. Talk with your health care provider

Tell your vaccination provider if the person getting the vaccine:

- Has had an **allergic reaction after a previous dose of COVID-19 vaccine** or has any **severe, life-threatening allergies**
- Has had **myocarditis** (inflammation of the heart muscle) or **pericarditis** (inflammation of the lining outside of the heart)
- Has had **multisystem inflammatory syndrome** (called MIS-C in children and MIS-A in adults)

In some cases, your health care provider may decide to postpone COVID-19 vaccination until a future visit.

People with minor illnesses, such as a cold, may be vaccinated. People who are moderately or severely ill, including with COVID-19, should usually wait until they recover.

COVID-19 vaccine may be given at the same time as other vaccines.

4. Risks of a vaccine reaction

- Pain, swelling, and redness where the shot is given, fever, tiredness (fatigue), headache, chills, muscle pain, joint pain, nausea, vomiting, and swollen lymph nodes can happen after COVID-19 vaccination.
- Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have been seen rarely after COVID-19 vaccination. These risks have been observed most frequently in adolescent and young adult males. The chance of this occurring is low.

People sometimes faint after medical procedures, including vaccination. Tell your provider if you feel dizzy or have vision changes or ringing in the ears.

As with any medicine, there is a very remote chance of a vaccine causing a severe allergic reaction, other serious injury, or death.

V-Safe is a safety monitoring system that lets you share with CDC how you, or your dependent, feel after getting COVID-19 vaccine. You can find information and enroll in V-Safe at vsafe.cdc.gov.

5. What if there is a serious problem?

An allergic reaction could occur after the vaccinated person leaves the clinic. If you see signs of a severe allergic reaction (hives, swelling of the face and throat, difficulty breathing, a fast heartbeat, dizziness, or weakness), call 9-1-1 and get the person to the nearest hospital.

Seek medical attention right away if the vaccinated person experiences chest pain, shortness of breath, or feelings of having a fast-beating, fluttering, or pounding heart after COVID-19 vaccination. These could be symptoms of myocarditis or pericarditis.

For other signs that concern you, call your health care provider.

Adverse reactions should be reported to the Vaccine Adverse Event Reporting System (VAERS). Your health care provider will usually file this report, or you can do it yourself. Visit the VAERS website at www.vaers.hhs.gov or call 1-800-822-7967. *VAERS is only for reporting reactions, and VAERS staff do not give medical advice.*

6. Countermeasures Injury Compensation Program


The Countermeasures Injury Compensation Program (CICP) is a federal program that may help pay for costs of medical care and other specific expenses of certain people who have been seriously injured by certain medicines or vaccines, including this vaccine. Generally, a claim must be submitted to the CICP within one (1) year from the date of receiving the vaccine. To learn more about this program, visit the program's website at www.hrsa.gov/cicp, or call 1-855-266-2427.

7. How can I learn more?

- Ask your health care provider.
- Call your local or state health department.
- Visit the website of the Food and Drug Administration (FDA) for COVID-19 Fact Sheets, package inserts, and additional information at www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines.
- Contact the Centers for Disease Control and Prevention (CDC):
 - Call 1-800-232-4636 (1-800-CDC-INFO) or
 - Visit CDC's COVID-19 vaccines website at www.cdc.gov/covid/vaccines/index.html.

Vaccine Information Statement
COVID-19 Vaccine

10/17/2024

OFFICE USE ONLY 

COVID-19 VIS

Updated COVID-19 Vaccine FAQs for Long Term Care Settings

COVID-19 FAQ for LTCF

UPDATED COVID-19 VACCINE FAQs FOR LONG-TERM CARE SETTINGS

Reflects CDC's updated COVID-19 vaccine recommendations.

ELIGIBILITY

1. Who is eligible to receive updated COVID-19 vaccines?

- Updated COVID-19 vaccines are recommended for everyone 6 months and older.
- Adults 65 years and older are recommended to receive two doses of updated 2024-2025 COVID-19 vaccine separated by 6 months (minimum interval 2 months).
- Individuals 6 months and older who are moderately or severely immunocompromised are also recommended to receive two doses of updated 2024-2025 COVID-19 vaccine separated by 6 months (minimum interval 2 months) and may receive additional doses in discussion with their healthcare provider.

Timing and other details are available at bit.ly/timingguide.

2. Which COVID-19 vaccines are available?

- Moderna and Pfizer-BioNTech COVID-19 vaccines are authorized for use in children 6 months-11 years.
- Spikevax (by Moderna) and Comirnaty (by Pfizer-BioNTech) are licensed for use in people 12 years of age and older.
- Novavax is authorized for use in people 12 years of age and older.

3. What if someone recently had a COVID-19 infection?

- People who recently had SARS-CoV-2 infection may consider delaying a COVID-19 vaccine dose by 3 months from symptom onset or positive test (if infection was asymptomatic). Individual factors such as [risk of severe COVID-19](#) and current indicators of community transmission should be taken into account when determining whether to delay getting a COVID-19 vaccination after infection. For more information, refer to [Interim Clinical Considerations for Use of COVID-19 Vaccines](#).

6. What are the benefits of an updated vaccine?

4. Can COVID-19 vaccines and other vaccines be administered at the same time?

strains of the virus which causes

a dependable way to build

italization, and death from
to reduce the risk of long COVID
infection does occur.

older [stay up to date](#) on COVID-

es include redness and swelling at

cines?

idents and staff.

ut current recommendations and
[Vaccines.gov](#).

[Facilities Resources](#)
[COVID-19 Vaccines](#)

nistration of all age-appropriate doses of
cific contraindications exist at the time of the

ing September or October.

ie 75 years of age and older and those 60-
[of severe RSV disease](#), including those
care facilities.

dated vaccine?

onths and older stay up to date on COVID-
of severe consequences of COVID-19 and
:

[S](#)

[ed](#)

[ons](#) that increase risk of getting very sick
heart, lung, or kidney disease; diabetes; or

is immunocompromised, at higher risk for
ted due to age or other reasons.
ated dose should get it now. (See additional
recently had a COVID-19 infection).

kely to mount an adequate immune
e eligible for a monoclonal antibody product
d [pemivibart](#) (Pemgarda™). However, it is
ngarda™ is **not** a substitute for vaccination.
y derive benefit from COVID-19 vaccination
dividuals who have recently received a
e administered at least 2 weeks after

November 2024

November 2024

Updated COVID-19 Vaccine FAQs

November 2024



Fall and Winter Immunization Guide

COVID-19 and Flu Updated 2024-25 Vaccines

Everyone 6 months
and older



cdc.gov/respiratory-viruses/prevention/immunizations.html

RSV Immunization to Protect Babies

Vaccine
Pregnant parents
during weeks 32-36
of pregnancy during
RSV season

OR

Monoclonal Antibodies
Babies entering or
born during the RSV
season



RSV Vaccine for Older Adults

(currently, older adults only need to get
the RSV vaccine once; not annually)

People ages 60 and
over at high risk of
severe RSV

AND

Everyone ages 75
and older



[CDC Fall & Winter Immunization Guide](#)



Risk Less. Do More. Campaign

- A U.S. Dept. of Health and Human Services (HHS) campaign to increase awareness of, confidence in, and uptake of flu, COVID-19, and RSV immunizations in at-risk populations including
 - Adults ages 60 and older
 - Adults living in long-term care facilities (LTCF)
- Fact sheets, social media graphics/videos, posters available on [HHS website](https://www.hhs.gov)

People of all ages need WHOOPING COUGH VACCINES



DTaP for young children

- ✓ 2, 4, and 6 months
- ✓ 15 through 18 months
- ✓ 4 through 6 years

Tdap for preteens

- ✓ 11 through 12 years

Tdap for pregnant women

- ✓ During the 27-36th week of each pregnancy

Tdap for adults

- ✓ Anytime for those who have never received it

www.cdc.gov/whoopingcough



[Pertussis Infographic](#)

Measles Protection for Travel

Measles is a plane ride away.

Since measles is still common in many countries, **unvaccinated travelers** continue to **get measles in other countries and bring it into the U.S.**, and spread it to others.



Get Vaccinated:

Bring home fun souvenirs, photos, and fantastic memories – **NOT measles!**



Make sure you are up to date on your **measles mumps rubella (MMR)** vaccine, including before travelling internationally. Ask your doctor, if you have received all recommended doses of MMR for best protection against measles.



U.S. Department of
Health and Human Services
Centers for Disease
Control and Prevention



Measles is still common in many parts of the world. Unvaccinated travelers who get measles in other countries continue to bring the disease into the United States.

Give your child the best protection against measles with **two** doses of measles-mumps-rubella (MMR) vaccine:



1st
dose at
**12-15
months**

2nd
dose at
**4-6
years**

Traveling abroad with your child?

Infants 6 to 11 months old need 1 dose of measles vaccine before traveling abroad. Children 12 months and older should receive 2 doses before travel. Check with your pediatrician before leaving on your trip to make sure your children are protected.




[CDC Measles & Travel Page](#) | [CDC Measles Travel Infographic](#) | [CDC Travel Infographic 2](#)

Vaccine Management

Josh Pocus, My Turn, and Claudia Aguiluz, myCAvax

What's New in My Turn? – Release 54

New updates for Patients, Clinic Managers, and Vaccine Administrators launched on **Wednesday, October 30, 2024!**



Release Highlights



- ✓ Patients receive a satisfaction survey via email the day after their appointment
- ✓ Added an error message if the 'Clinic End Date' exceeds one year from the start date on the Testing site information form
- ✓ Patients can see updated error messages when no clinics are found in the search on the 'Select a location' page
- ✓ Renamed the 'Walk-ins welcome' tag to 'Accepts walk-ins'
- ✓ Enhanced the Testing site information form

My Turn Public

Release Highlights



- ✓ Disabled the 'This contact is also a Prescribing Provider' checkbox after three providers are added, as only three can be created on the digital enrollment flow
- ✓ Displayed all fields in the 'Clinic Name and Location' section on the clinic creation flow
- ✓ Renamed the 'Set Clinic Visibility' section to 'Vaccine Locator,' repositioned it, and updated the toggle to 'Show on My Turn Vaccine Locator' on the clinic creation flow
- ✓ Renamed the 'Walk-ins welcome' checkbox to 'Accepts walk-in patients' on the clinic creation flow, 'Clinic' page, and Vaccine Locator form
- ✓ Modified 'Details' tab on the 'Clinic' page with updated checkboxes and fields
- ✓ Added an error message if the 'Clinic End Date' exceeds one year from start date on the clinic creation flow and 'Clinic' page
- ✓ Added new Covid-19 and Flu products on the CQE flow
- ✓ Added new 'Route' and 'Injection Site' values on the CSV / Inline bulk upload flows
- ✓ Added an error message if no vaccine is selected when submitting the Vaccine Locator form
- ✓ Clinic owner receives deactivation reminder emails for inactive clinics

My Turn Clinic

My Turn – Known Issues and Workarounds



Known Issues

Clinics with no activity for 90 days are not being deactivated automatically and reminder emails to renew these are not being sent out.





Workaround / Next Steps

- ✓ Estimated Fix: November 20, 2024
 - ✓ The team is currently working on a fix for both items. Latest date it will be resolved is by December 4, 2024.

Vaccine Locator – Opt-In today!

Program Locations that have Opted-In:



Please take some time to opt-in, **preferably right now!** We want patients to be able to find you.

We want to congratulate **Los Angeles County** for their participation and being the top county with **147 Locations** opted-in!

Data as of 11/14/24



Thank you for opting into the Vaccine Locator. By doing so, you are ensuring that patients can easily find your locations. Your participation is invaluable in **helping patients access the care they need.**

The Alliance For Community Wellness	La Maestra Community Health Centers
Family HealthCare Network	WellSpace Health
ARYA MEDICAL GROUP	AAA Comprehensive Healthcare
Dizon Medicine Urgent Care	Arlington Prescription Pharmacy
First Pediatrics Medical Group	Prime Family and Walk-In Clinic
Niloo Medical Group INC	Valley Healthcare Centers
El Proyecto del Barrio, Inc	Pacific Central Coast Health Centers
AltaMed Health Services Corporation	Golden Oak Pediatrics
Family Health Care Centers of Greater Los Angeles	yasmeen gangani pediatrics
Emanate Health Med Group Pediatrics	Q-Bit Wellness
Public Health Division	County of Los Angeles Department of Public Health
Coppertower Family Medical Center Inc dba	Moreno Valley Physicians Associates, A Medical Corporation
Alexander Valley Healthcare	Hollywood Sunset Free Clinic
Mono County Health Department	Blessing Community Health Center
Humboldt County Public Health	La Clinica de La Raza
San Benito County Public Health Services	DR. SATEY PEDIATRIC ADOLESCENT MEDICAL CLINIC
San Bernardino County Department of Public Health	San Lucas Pediatric Clinic, Inc.
Napa County Health and Human Services Agency	Pediatrics R US INC
County of Placer	J. Shafai, M.D., Inc.
Fresno County Department of Public Health	Dr. Naomi Sato
Sacramento County Public Health	Clinica Medica Familiar- PHN, Inc.
Kings County Department of Public Health	Merced Faculty Associates Medical Group, Inc
Huong Quy, D.O.	CRESENCIA D BANZUELA MD. INC.
S4 Pharmacy,INC.	Arnold J. Blustein, MD, Inc.
Riverside University Health System-Community Health Center	DEL ROSARIO MEDICAL CLINIC, INC.
Angeles Medical Clinic	Pamela V. Atienza, MD, A Professional Medical Corporation
Loan Truong	San Juan Pediatrics
National City Fire Department	Greg M Oji
DE ANZA CLINIC	ABC Pediatrics Medical Center
DAP Health	SARASA KUMAR, M.D,INC
Clover Pharmacy	NASSER AZIZ-ZADEH M.D.
Community Medical Centers, Inc.	

myCAvax Release Roadmap

Past Release October 16, 2024 (R51)

Release 51

VFC

- ✓ Bulk Allocation

VFC/VFA/317

- ✓ Corrections Needed orders will handle rejected line items and expired lots
- ✓ Field Reps will be notified when an order is placed with an open hold
- ✓ Only VtrckS Relevant changes will be sent to VtrckS
- ✓ Pending Status will now require a status reason
- ✓ Internal Comments will be saved as notes on an order instead of in the text box
- ✓ Providers will see variance columns when creating orders
- ✓ Providers will be able to save progress on draft and corrections needed orders
- ✓ Provider will only be able to have one open order at a time

Current Release November 20, 2024 (R52)

Release 52

VFC/VFA/317

- ✓ 2025 Recertification for VFC
- ✓ Enhancements to the VFA and LHD 317 Recertification
- ✓ Duplicate 'Staff Management Requests' will be prevented
- ✓ CDPH will have the ability to 'Expire' Orders manually

Future Release January 8, 2025 (R53)

Release 53

VFC

- ✓ VFC Flu Prebook

VFC/VFA/317

- ✓ Orders will be sorted by Submitted Date on CDPH Order Review
- ✓ Storage Unit Changes will no longer create holds

All Programs

- ✓ View Shipments at program location level
- ✓ Holds will be automatically closed with a unit is marked 'No Longer in Use'
- ✓ Filter out provider inventories that are not being used

What's Next in myCAvax? – Release 52

New updates for providers will launch on **November 20, 2024!** Recertification updates will NOT be visible until VFC Opens up 2025 VFC Recertification.

Release Highlights



Duplicate staff management requests avoided

- ✓ Only one staff management request can be submitted at a time for the 'Organization Vaccine Coordinator,' 'Provider of Record,' and 'Designee' roles to prevent duplicates.

2025 VFC Recertification*

- ✓ Recertification will now be available for Vaccine for Children program in myCAvax.
- ✓ New 'Recertification' page to view status of all program location at once.
- ✓ Program-specific logos added in each recertification step.

- ✓ For Key Practice Staff, 2 new columns are added to indicate VFC Training Requirement completion– 'EZIZ Username' and 'Training Complete.'
- ✓ A new section for adding 'Ultra Frozen storage' is added.
- ✓ If a new vaccine storage is added, a 'Certificate of Calibration' upload is required.
- ✓ As providers confirm Provider Populations served, questions are added to confirm the practice is offering ACIP recommended vaccines according to populations served.
- ✓ As part of recertification, providers will have the opportunity to complete the Opt-in Form for 'My Turn Vaccine Locator'

***Updates are in preparation for VFC's 2025 Recertification (Anticipated by Mid December 2024)**

myCAvax – Known Issues and Workarounds



Known Issues

Unable to Accept/Reject Transfers

- ✓ Providers are currently unable to Accept or Reject their transfers due to a system bug on the provider side



Workaround / Next Steps

- ✓ Estimated Fix: 11/20/2024
- ✓ In the meantime, please contact the PCC with the necessary detailed information after receiving the transfer, who will then be able to accept or reject your transfer on your behalf

myCAvax – Known Issues and Workarounds



Known Issues

Shipping Incidents pulling all Vaccines in from the Selected Order

- ✓ When a provider submits a shipping incident in myCAvax and selects the related order, it would automatically pull every single vaccine product in the order even if only 1 vaccine product was affected.

File size limits when uploading excursions in myCAvax

- ✓ Providers have been encountering difficulties when trying to upload excursion documents in myCAvax that exceed the file size limit permitted in the system.



Workaround / Next Steps

- ✓ Providers should 'un-select' by using the 'Clear Row' trash can for vaccine products that were not affected in the shipping incident.
- ✓ Currently, the file size limit in myCAvax is 3 MB. You will be unable to properly submit your Excursion report if your file size exceeds 3 MB. In that case, upload a reduced file under 3 MB to submit the report and upload larger file(s) post-submission. Refer to the Uploading Temperature Data Reports section in the 'Recording Temperature Excursions' Job Aid to learn more about uploading additional documents after submission.

myCAvax – Known Issues and Workarounds



Known Issues

Deleting Incorrect Excursion Events

- ✓ Providers are unable to delete incorrect excursion events from the system. If there's the need to delete one, providers must contact the VFC Customer Service Center for assistance.

Providers unable to report multiple excursions within the same report

- ✓ This is something providers were able to do in SHOTS through MyVFCvaccines. Some providers may experience multiple temperature excursions within the same day or within a couple of days. Providers don't want to have to submit a new report for each excursion if affected inventory is all the same.



Workaround / Next Steps

- ✓ CDPH gathers all excursion events that need to be deleted and have them removed / cleaned up in the next myCAvax release (11/20/2024)
- ✓ Providers should submit **one report** and report the coldest temp within the time frame as the minimum temperature and the warmest temp within the time frame as the maximum temperature. Then they will report the date and time of the first excursion and ensure that total time out range is the cumulative total time for all temp excursions. In the 'Comments' section, they should note that they had multiple cold / warm excursions within a certain timeframe.

Novavax Vaccine – Important Reminders

- Novavax doses that expired on **October 31, 2024** should be removed from vaccine storage units, **reported as expired waste** in myCAvax and **returned** to McKesson, per usual.
- Novavax will be **NOT** be receiving a shelf-life extension for doses that have an expiry on November 30, 2024. Upon expiration, doses will need to be returned to McKesson.
- Due to the short expiry dates for inventories of Novavax, CDC will not ship any additional doses. Therefore, ordering for Novavax is **turned off** for both VFC and BAP temporarily until additional doses are received at McKesson. Any unapproved order in myCAvax will be rejected.
- An [Expiration Look-Up Tool](#) is available for providers to check for most up-to-date information about expiry administration.

Planning for Vaccine Holiday Shipping

- As we approach the Thanksgiving and Christmas holiday shipping schedules, providers are strongly encouraged to **order early** during the winter holidays!
 - **Limited deliveries** will occur the week of November 25, 2024
 - VFC orders placed after 11/15/2024, **may not ship** until December 2, 2024
 - CA BAP orders placed after 11/19/2024, **may not ship** until December 2, 2024
- Please maintain **4 weeks** of inventory to prevent vaccine outages if orders are delayed due to weather and/or carrier interruptions.
- If you expect orders to arrive before the holidays, please keep in mind that routine shipments from McKesson can take up to 4 business days to process before being shipped, ONCE orders are sent to CDC. Some shipments may take longer than 4 days to process and ship if the provider does not have regular daily business hours (M–F, 8:00 am – 5:00 pm)

November 2024 Routine Vaccine Distribution Holiday Calendars & Holds



Monday	Tuesday	Wednesday	Thursday	Friday
October 28	29	30	31	November 01
04	05	06	07	08
11 Veteran's Day Holiday Hold - Vaccine Delivery Blackout	12	13	14	15 VFC Orders placed after this date may not ship until 12/2/2024
18	19 Orders processed after this date may not ship until 12/02/24	20	21	22
25	26	27	28	29
Thanksgiving Holiday Holds – Vaccine Delivery Blackout				




- *Limited delivery on November 26 and 27 for urgent orders only. Providers with questions or concerns about vaccine deliveries should contact the Provider Call Center at ProviderCallCenter@cdph.ca.gov or call at 833-502-1245.
- Order processing is dependent on the date of LHD or CDPH approval. If an approval deadline is missed, the order will be processed the following CDPH Transmission date.
- Delivery windows are dependent on provider's days/hours of operation. **Update hours in myCAvax for any holiday or temporary closures.**
- Watch for emails regarding order confirmations, advance shipment notices of vaccine, and temperature monitoring alerts.

IMM-1548 11/6/24

Reminder: Submit Feedback in myCAvax

- Feedback is important to help us understand what's working well, what are some existing pain points and challenges you are encountering while using myCAvax.
- Please take the time to submit feedback using the 'Rate your experience' pop-up window. You are helping us **continue to refine and enhance myCAvax for you!**



The screenshot shows a feedback form titled "Rate your experience". Below the title, it says "Your feedback will help us make improvements in future". There are five yellow stars for rating. Below the stars, it says "Please provide your general feedback(optional)" followed by a text input field. At the bottom right, there is a red "Submit" button.

Examples of feedback we have received:

"Ordering was fairly easy."

"New portal is very organized!"

"Nice, clean, easy to use."

"Immunizations we don't use should be taken off the order so we can go through the order faster."

"Fewer tabs and simpler process to find inventory and previous orders."

"Supplemental orders should be allowed without a complete inventory.. Also, the date formatting should be changed to not need slashes when complete dates are entered."



Resources and Q&A

Leslie Amani and CDPH Subject Matter Experts

Resources on EZIZ

Home
Vaccine Programs
Vaccine Management
Storage Units
Temperature Monitoring
Training & Webinars
Clinic Resources
Patient Resources

[Link to EZIZ Homepage](#)



ENHANCED BY Google

A one-stop shop for immunization training and resources.

Home

Vaccine Programs

Vaccine Management

Storage Units


Temperature Monitoring

Training & Webinars


Clinic Resources

Patient Resources

California's Vaccine Programs

**VFC**
California
Vaccines for
Children Program

**VFA**
California
Vaccines for
Adults Program

**BAP**
California
Bridge Access
Program

**LHD 317**
Local Health
Department
317 Program

Ordering & Vaccine Management

- MyCAvax (VFC, VFA, BAP, and 317)
- MyVFCvaccines (read-only)

Storage Requirements


- Vaccine Storage Units
- Digital Data Loggers

Contact VFC

Phone: (877) 243-8832
Hours:
Mon-Thurs, 9AM-4:30PM
Friday, 9AM-4PM
Send us an email
Fax: (877) 329-9832

- VFC Field Representatives
- Find VFC providers
- Sign up for EZIZ emails
- Frequently Asked Questions

Hot Topics

**CDPH Immunization Updates for Providers**

- AIM Champion Awards
- S&H Job Aids for VFC, VFA, LHD 317 and SGF programs
- Reporting & Return of Nonviable Vaccines
- Reporting Excursions & Manufacturer Contacts
- COVID-19 Vaccine Resources
- VFC and Birthing Hospitals

Popular Resources

Protect Your Patients Against RSV!

- RSV Immunization FAQs
- Resources for Providers and Patients

Vaccine Resources

- Vaccine Fact Sheets
- Flu
- Measles
- Mpox
- Pertussis
- Schedules & Recommendations
- For Pharmacies

CDPH Applications

- myCAvax (ordering and management)
- MyVFCvaccines (read-only)
- My Turn (COVID/Flu Vaccine Administration System)
- CAIR (California Immunization Registry)
- My DVR (Digital Vaccine Records)
- CAIR-ME (Medical Exemptions from Immunizations for School and Child Care)

Alerts!

**2024-25 COVID Vaccine**

- COVID-19 Vaccine Timing Guide (8/30/24)
- Calendario de la Vacuna COVID-19 (9/10/24)
- COVID-19 Vaccine Product Guide (9/9/24)
- More Resources: For Providers | For Patients
- Vaccine Ordering and Manufacturing Info

**VFC vaccine ordering and management is now live at myCAvax!**

Learn more about myCAvax move, recorded trainings and FAQs!

**Holiday Ordering and Distribution for SGF**

- September/October Calendar

VFC Memos

Vaccine Order Status

From CDPH

VFC Program Letters

- VFC 2024-2025 Flu Vaccine Ordering Information September 6
- myCAvax is Now the VFC Vaccine Management System June 14
- Clinical Letter for Penbraya (MenABCWY vaccine) May 16
- VFC is Moving to a New Vaccine Management System – myCAvax May 13

 CDPH

Immunization
Branch

61

Updated
10.31.24

Provider FAQs

COVID-19 Vaccine and Therapeutics FAQs v.149_10.31.2024 1

COVID-19 Vaccine and Therapeutics FAQs

For providers administering COVID-19 vaccine and treating COVID-19.
Providers may also visit [EZIZ COVID-19 Resources](#) for information and updates.

Directions: [Click on a category to be directed to related FAQs.](#)

New and Updated FAQs	2
COVID-19 Vaccine Access	2
California Bridge Access Program (BAP)	4
Vaccines For Children (VFC) Program	6
Vaccine Administration	6
Vaccine Storage & Handling	10
Reporting	11
COVID-19 Therapeutics	13
Support & Resources	14



Q: Are there recommendations for a second dose of 2024 – 2025 COVID-19 vaccine?

A: On October 23, 2024, the Advisory Committee on Immunization Practices (ACIP) recommended a second dose of the 2024 – 2025 COVID-19 vaccine 6 months after the first dose to people:

- 65 years and older
- 6 months – 64 years who are moderately or severely immunocompromised
 - additional doses (i.e., 3 or more) of 2024 – 2025 COVID-19 vaccine may be given to immunocompromised people 6 months – 64 years under [shared clinical decision making](#)

Please note the **minimum interval between COVID-19 vaccine doses is 2 months**. Refer to the following CDC resources for more information: [ACIP Recommendations](#), and [Clinical Guidance for COVID-19 Vaccination](#).



Q: Where can providers find information on COVID-19 treatment?

A: Information on COVID-19 treatment including who qualifies, treatment options, patient assistance programs, and related resources can be found on the [CDC COVID-19 Treatment Clinical Care for Outpatients page](#).

[Link to COVID-19 Provider FAQs](#)

COVID-19 Vaccine Product Guide 2024 – 2025

COVID-19 Vaccine Product Guide

CDPH

Check vaccine labels and FDA materials before use to avoid mix-ups.
[Package inserts](#) and [EUA fact sheets](#) supersede info on vials and carton.

Pfizer

Infant/Toddler
6 months–4 years

Pediatric
5–11 years

Comirnaty
12+ years

Comirnaty
12+ years

2024-25 Formula

2024-25 Formula

Single-Dose Vial
2024-25 Formula
image not available

2024-25 Formula

Packaging	Yellow Cap	Blue Cap	Pre-Filled Syringe
Doses Per Vial	3 doses	1 dose	1 dose/syringe
Carton Size	30 doses	10 doses	10 doses
NDC-Unit of Sale (carton)	59267-4426-02	59267-4438-02	00069-2403-10
NDC-Unit of Use (vial/syringe)	59267-4426-01	59267-4438-01	00069-2403-01
CVX Code	308	310	309
CPT Code	91318	91319	91320
Program Availability	VFC	VFC	Not available
Min. Standard Order*	30 doses	10 doses	10 doses

Storage Limits Before Puncture: Label vaccine with expiration and use-by dates.

Shipping	Ships from manufacturer with dry ice between -90°C and -60°C (-130°F to -76°F)	2° to 8°C (36°F to 46°F)
ULT	Until expiration date at -90°C to -60°C (-130°F to -76°F)	
Thermal Shipper		
Freezer		
Refrigerator	Up to 10 weeks at 2°C to 8°C (36°F to 46°F). Do not refreeze. Write the use-by date on carton—not to exceed expiration.	Until expiration at 2°C to 8°C
Expiration Date	Check the date on the product/carton, or for thawed products refer to the written use-by date.	Check label.

Administration

Diluent (supplied)	1.1 mL per vial	Do not dilute	Do not dilute	N/A
Dose Volume & Dose	0.3 mL 3 mcg dose	0.3 mL 10 mcg dose	0.3 mL 30 mcg dose	0.3 mL 30 mcg dose
Refrigerator Thaw Time	Carton/Vial: Up to 2 hours at 2° to 8°C (36°F to 46°F) (Do not refreeze)			N/A
Room Temp Thaw Time	Vial: 30 minutes at up to 25°C (77°F) (Do not refreeze)			N/A
Total Time at Room Temp	Up to 12 hours (including thaw time) at 8°C to 25°C (46°F to 77°F)			

Storage Limits After Puncture (Multi-dose vials): Record puncture and use-by time on vial label.

Use-By Limit (Discard Time After 1st Puncture)	Discard 12 hours after dilution. Keep at 2°C to 25°C (35°F to 77°F)	N/A	N/A	Use immediately after removing cap, within 4 hours.
--	---	-----	-----	---

* Orders for privately purchased vaccines may have different order minimums.

California Department of Public Health, Immunization Branch

IMM-1399 (9/24/24) Page 1 of 3

COVID-19 Vaccine Product Guide

CDPH

Check vaccine labels and FDA materials before use to avoid mix-ups.
[Package inserts](#) and [EUA fact sheets](#) supersede info on vials and carton.

Moderna

Pediatric
6 months–11 years

Spikevax
12+ years

2024-25 Product

2024-25 Product

Packaging	Pre-Filled Syringe	Pre-Filled Syringe
Doses Per Vial	1 dose/syringe	1 dose/syringe
Carton Size	10 doses	10 doses
NDC-Unit of Sale (carton)	80777-0291-80, Blister-sealed: 80777-0291-81	80777-0110-96, Blister-sealed: 80777-0110-93
NDC-Unit of Use (vial/syringe)	80777-0291-09	80777-0110-01
CVX Code	311	312
CPT Code	91321	91322
Program Availability	VFC	VFC, CA BAP
Min. Standard Order*	10 doses	10 doses

Storage Limits Before Puncture: Label vaccine with expiration and use-by dates.

Shipping	Ships frozen between -50°C and -15°C (-58°F and 5°F)	2° to 8°C (36° to 46°F)
ULT		
Thermal Shipper		
Freezer	Until expiration at -50°C to -15°C (-58°F to 5°F)	
Refrigerator	Up to 60 days (not to exceed expiration date) at 2–8°C (36–46°F)	Until expiration at 2–8°C (36–46°F)
Expiration Date	Check Moderna product website or QR code.	Check product website.

Administration

Diluent	N/A	
Dose Volume & Dose	0.25 mL 25 mcg	0.5 mL 50 mcg
Refrigerator Thaw Time	Syringe: 1 hour Carton: 2.5 hours	
Room Temp Thaw Time	Syringe: 45 minutes, Carton: 2 hours and 15 minutes	
Total Room Temp Time	Store up to 12 hours at 8°C to 25°C (46°F to 77°F)	

Storage Limits After Puncture

Use-By Limit	N/A. Discard after single use.	
--------------	--------------------------------	--

* Orders for privately purchased vaccines may have different order minimums.

California Department of Public Health, Immunization Branch

IMM-1399 (9/24/24) Page 2 of 3

COVID-19 Vaccine Product Guide

CDPH

Check vaccine labels and FDA materials before use to avoid mix-ups.
[Package inserts](#) and [EUA fact sheets](#) supersede info on vials and carton.

Do Not Use Deauthorized Products:

Use only COVID-19 vaccine products updated for 2024-25.

Pfizer

Infant/Toddler
6 months–4 years

Pediatric
5–11 years

Adol/Adult (Comirnaty)
12+ years

2021 Monovalent

2021 Bivalent

2023-24

2021 Monovalent

2021 Bivalent

2023-24

2021 Monovalent

2021 Bivalent

2023-24 single-dose vial

2023-24 syringe

Moderna

Infant/Toddler
6 months–5 years

6 months+

Pediatric
6–11 years

Pediatric
6 mos–11 yrs

Adol/Adult (Spikevax)
12+ years

2021 Monovalent

2021 Bivalent

2023-24

2021 Monovalent

2021 Bivalent

2023-24 single-dose vial

2021 Monovalent

2023-24 single-dose vial

2023-24 syringe

Janssen (J&J)

Adult
18+ years

2021 Monovalent

Novavax

Primary 12+ yrs
Booster 18+

2022 Monovalent

2023-24 multi-dose vial

California Department of Public Health, Immunization Branch

IMM-1399 (9/24/24) Page 3 of 3

COVID-19 Vaccine Product Guide 2024 - 2025

CDPH

Immunization
Branch

63

COVID-19 Vaccine Timing 2024 – 2025

COVID-19 Vaccine Timing 2024-25 –Routine Schedule

For online version and details view [Interim Clinical Considerations for Use of COVID-19 Vaccines](#).
Schedule is subject to change.

Age*	Vaccine	If unvaccinated:			If had any prior doses, give 2024-25 doses:	
6 months–4 years†	Pfizer–Infant/Toddler	1st Dose	3-8 weeks**	2nd Dose	≥8 weeks	3rd Dose
	Moderna–Pediatric*	1st Dose	4-8 weeks**	2nd Dose		
5–11 years	Moderna–Pediatric*	1 Dose				
	Pfizer–Pediatric	1 Dose				
12+ years	Pfizer–Adol/Adult (Comirnaty)	1 Dose				
	Moderna–Adol/Adult (Spikevax)	1 Dose				
	Novavax	1st Dose	3-8 weeks**	2nd Dose		
6 months§					Ages 65+ years: Additional Dose Moderna/ Pfizer/ Novavax	
					Ages 12-64 years: ≥2 months ① 2024-25 Moderna/ Pfizer/ Novavax	
					Ages 65+ years: ≥2 months ① 6 months§ ②	

* See [CDC recommendations](#) for children transitioning from a younger to older age group

† Children 6 months – 4 years should receive the same brand of the updated vaccine as the prior doses they received.

** An 8-week interval may be preferable for some people, especially for males 12-39 years.

‡ All Moderna doses 6 months – 11 years are 0.25 mL (25 mcg).

^ Janssen (J & J) vaccine has been deauthorized. Follow schedule for 12+ years for any prior doses.

§ Minimum interval 2 months.

California Department of Public Health, Immunization Branch

IMM-1396 (10/28/24) Page 1 of 2

* See [CDC recommendations](#) for children transitioning from a younger to older age group

† Children 6 months – 4 years should receive the same brand of the updated vaccine as the prior doses they received.

** An 8-week interval may be preferable for some people, especially for males 12–39 years.

†† All Moderna doses 6 months – 11 years are 0.25 mL (25 mcg).

^ Janssen (J & J) vaccine has been deauthorized. Follow schedule for 12+ years for any prior doses.

§ Minimum interval 2 months.



California Department of Public Health, Immunization Branch

IMM-1396 (10/28/24) Page 1 of 2

COVID-19 Vaccine Timing 2024-25 if Moderately/Severely Immunocompromised									
Age	Vaccine	If unvaccinated:					If had any prior doses give 2024-25 doses:		
6 months–4 years	Pfizer–Infant/Toddler	1st Dose	3 weeks	2nd Dose	≥8 weeks	3rd Dose	6 months†	Additional Dose(s)*	1 prior dose: 3 w 1 ≥8 w 2 ≥2 prior doses: ≥8 w 1
	Moderna–Pediatric	1st Dose	4 weeks	2nd Dose	≥4 weeks	3rd Dose	6 months†	Additional Dose(s)*	1 prior dose: 4 w 1 ≥4 w 2 2 prior doses: ≥4 w 1
5–11 years	Moderna–Pediatric	1st Dose	4 weeks	2nd Dose	≥4 weeks	3rd Dose	6 months†	Additional Dose(s)*	≥3 prior doses**††: ≥8 w 1 (for ages 5+ yrs, Pfizer dose is also OK)
	Pfizer–Pediatric	1st Dose	3 weeks	2nd Dose	≥4 weeks	3rd Dose	6 months†	Additional Dose(s)*	1 prior dose: 3 w 1 ≥4 w 2 2 prior doses: ≥4 w 1
12+ years	Pfizer–Adol/Adult (Comirnaty)	1st Dose	3 weeks	2nd Dose	≥4 weeks	3rd Dose	6 months†	Additional Dose(s)*	≥3 prior doses**††: ≥8 w 1
	Moderna–Adol/Adult (Spikevax)	1st Dose	4 weeks	2nd Dose	≥4 weeks	3rd Dose	6 months†	Additional Dose(s)*	1 prior dose: 4 w 1 ≥4 w 2 2 prior doses: ≥4 w 1 ≥3 prior doses**††: ≥8 w 1
	Novavax	1st Dose	3 weeks	2nd Dose			6 months†	Additional Dose(s)*	≥1 prior doses**††: ≥2 m 1

* Further doses may be given under shared clinical decision-making at a minimum interval of 2 months. See [Table 2](#) for vial and dosage.

** Ages 5–11 years may be given Moderna or Pfizer after ≥3 prior doses. Ages 12+ years may be given Moderna, Pfizer, or Novavax.

§ Minimum interval 2 months.





California Department of Public Health, Immunization Branch

IMM-1396 (10/28/24) Page 2 of 2

[Updated COVID-19 Vaccine Timing Guide 10.28.24](#)

CDPH Office of Communications

Sign Up for the CDPH Communications Tools & Information Newsletter



Sign up to receive weekly email updates from the California Department of Public Health. Get the latest public health guidance and communications tools & resources for advancing public health in California and beyond.

First Name*

Last Name*

E-mail*

Organization

Sign up to receive the
[CDPH Office of Communications Tools & Information Newsletter](#)

Vaccine Support

Provider Call Center

Dedicated to medical providers and Local Health Departments in California, specifically addressing questions about State program requirements, enrollment, and vaccine distribution.

- For myCAvax Help Desk inquiries: myCAvax.hd@cdph.ca.gov
- For My Turn Clinic Help Desk inquiries: MyTurn.Clinic.HD@cdph.ca.gov
- For all other inquiries: providercallcenter@cdph.ca.gov
- Phone: (833) 502-1245, Monday through Friday from 8AM–5PM

myCAvax

- Virtual Assistant resolves many questions but will direct you to the Provider Call Center queue for live assistance!
- Knowledge Center houses key job aids and videos that are updated every release. Once logged in, you can access job aids from the myCAvax homepage (or at various places throughout the system) using the links as shown below.



Need help? View our job aids in the [Knowledge Center](#), or [contact us](#).



COVID-19 Therapeutics Resources

Type of Support


Description

Updated 7.8.24



Clinical Guidance

For general Therapeutics questions, please email: cdphtherapeutics@cdph.ca.gov



General Information

[CDPH COVID-19 Treatments Webpage](#) (provides general information for healthcare providers, allocations, distribution and ordering, drug facts sheets, and additional resources)

[Finding COVID-19 Treatments](#) (questions and answers for the public on finding COVID-19 treatments)

[COVID-19 Therapeutics Best Practices Checklist](#) (testing, prescribing, dispensing, and more for providers)


[Frequently Asked Questions document](#) for clinics, providers, and pharmacists



Locating Resources

Finding Providers and Test-to-Treat Sites

- [COVID-19 Therapeutics Locator](#) (find COVID-19 medications near you)
- [Information Page for Test-to-Treat](#) Program (hhs.gov)



[Archive LHD Therapeutics SharePoint](#)

For access to previously recorded LHD webinars and slides contact: rphoadmin@cdph.ca.gov

For Information on how to registers for HPOP reporting information, use link below.

- [CDPH Therapeutics HPoP Account Verification & Reporting](#) information



Questions

For general CDPH Therapeutics questions, please email cdphtherapeutics@cdph.ca.gov

For ordering, program inquiries, signing up new HPOP Accounts: please e-mail cdphtherapeutics@cdph.ca.gov

CDPH Provider Webinars and Trainings

Week of November 18, 2024


	Monday 11/18	Tuesday 11/19	Wednesday 11/20	Thursday 11/21	Friday 11/22
Live Webinars and Training	No Events Scheduled at this time				
View On Demand	<ul style="list-style-type: none">• CDPH Immunization Branch Archived Provider Webinars and Slides• AIM Vaccine Confidence Toolkit Webinar Series		<ul style="list-style-type: none">• Introduction to My Turn Onboarding (v. 1/4/22)• Latest Features in My Turn (Requires myCAvax Login)• myCAvax Release Notes for LHD and CDPH Users (Requires myCAvax Login)		
Help	Help Desk CDPH Provider Call Center: 1-833-502-1245, M-F 8am-5pm Email: providercallcenter@cdph.ca.gov My Turn: Help Desk Email: myturn.clinic.hd@cdph.ca.gov Onboarding Email: myturnonboarding@cdph.ca.gov myCAvax: Help Desk Email: mycavax.hd@cdph.ca.gov Mpox: Email: stdcb@cdph.ca.gov			Immunization Resources California's General Immunization Resources (eziz.org) RSV Immunization Resources Flu Vaccination Resources COVID-19 Vaccination Resources COVID-19 Treatments Mpox Vaccination Resources	

CDPH Provider Webinars and Trainings


Week of November 25, 2024

	Monday 11/25	Tuesday 11/26	Wednesday 11/27	Thursday 11/28	Friday 11/29
Live Webinars and Training				Happy Thanksgiving!	
View On Demand	<ul style="list-style-type: none">• CDPH Immunization Branch Archived Provider Webinars and Slides• AIM Vaccine Confidence Toolkit Webinar Series		<ul style="list-style-type: none">• Introduction to My Turn Onboarding (v. 1/4/22)• Latest Features in My Turn (Requires myCAvax Login)• myCAvax Release Notes for LHD and CDPH Users (Requires myCAvax Login)		
Help	Help Desk CDPH Provider Call Center: 1-833-502-1245, M-F 8am-5pm Email: providercallcenter@cdph.ca.gov My Turn: Help Desk Email: myturn.clinic.hd@cdph.ca.gov Onboarding Email: myturnonboarding@cdph.ca.gov myCAvax: Help Desk Email: mycavax.hd@cdph.ca.gov Mpox: Email: stdcb@cdph.ca.gov			Immunization Resources California's General Immunization Resources (eziz.org) RSV Immunization Resources Flu Vaccination Resources COVID-19 Vaccination Resources COVID-19 Treatments Mpox Vaccination Resources	

Q&A



During today's webinar, please click and open the Q&A icon to ask your questions so CDPH panelists and subject matter experts (SMEs) can respond.



[Links are in blue and underlined](#)

Thank you for attending!



**Immunization
Branch**

Next CDPH Immunization Updates for Providers
Friday, December 13, 2024

[CDPH Immunization Updates for Providers
Registration Link](#)